JOP20210250A1 - صياغة صلبة لمُعدلات تجميعة القفيصات - Google Patents

صياغة صلبة لمُعدلات تجميعة القفيصات

Info

Publication number
JOP20210250A1
JOP20210250A1 JOP/2021/0250A JOP20210250A JOP20210250A1 JO P20210250 A1 JOP20210250 A1 JO P20210250A1 JO P20210250 A JOP20210250 A JO P20210250A JO P20210250 A1 JOP20210250 A1 JO P20210250A1
Authority
JO
Jordan
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
JOP/2021/0250A
Other languages
English (en)
Inventor
Maria Jansens
Jan Snoeys
Oliver Lenz
Michaël Bertil S Anne
Claire Elisabeth Balmain
Abhishek Singh
Dycke Frederic Anne R Van
Joris Jozef Vandenbossche
Dominique Josiane W Verstraete
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/352,754 external-priority patent/US10973801B2/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of JOP20210250A1 publication Critical patent/JOP20210250A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

يتعلق الكشف الحالي بأشكال جرعة معوية صلبة من مثبط تجميعة القفيصات لعلاج الإصابة بعدوى فيروس الالتهاب الكبدي B.
JOP/2021/0250A 2019-03-13 2020-03-13 صياغة صلبة لمُعدلات تجميعة القفيصات JOP20210250A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (en) 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation

Publications (1)

Publication Number Publication Date
JOP20210250A1 true JOP20210250A1 (ar) 2023-01-30

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0250A JOP20210250A1 (ar) 2019-03-13 2020-03-13 صياغة صلبة لمُعدلات تجميعة القفيصات

Country Status (16)

Country Link
EP (1) EP3937928A1 (ar)
JP (1) JP2022524819A (ar)
KR (1) KR20210137484A (ar)
CN (1) CN113557016A (ar)
AU (1) AU2020235442A1 (ar)
BR (1) BR112021017525A2 (ar)
CA (1) CA3132095A1 (ar)
CR (1) CR20210481A (ar)
EC (1) ECSP21067052A (ar)
IL (1) IL286209A (ar)
JO (1) JOP20210250A1 (ar)
MA (1) MA55280A (ar)
MX (1) MX2021011030A (ar)
PE (1) PE20212107A1 (ar)
SG (1) SG11202109710QA (ar)
WO (1) WO2020183020A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
AU2019235522A1 (en) * 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2019235522A1 (en) * 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen

Also Published As

Publication number Publication date
EP3937928A1 (en) 2022-01-19
MA55280A (fr) 2022-01-19
ECSP21067052A (es) 2021-11-18
CA3132095A1 (en) 2020-09-17
KR20210137484A (ko) 2021-11-17
MX2021011030A (es) 2021-10-13
IL286209A (en) 2021-10-31
CR20210481A (es) 2021-10-25
PE20212107A1 (es) 2021-11-04
JP2022524819A (ja) 2022-05-10
SG11202109710QA (en) 2021-10-28
AU2020235442A1 (en) 2021-08-12
BR112021017525A2 (pt) 2021-11-23
WO2020183020A1 (en) 2020-09-17
CN113557016A (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
PH12020551421A1 (en) Capsid assembly modulator dosing regimen
JOP20180123A1 (ar) مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية
MX2020011808A (es) Combinaciones y metodos que comprenden un inhibidor del ensamblaje de la capside.
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201892034A1 (ru) Элиминация вируса гепатита в при помощи противовирусных агентов
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
GEP20146134B (en) Inhibitors of hepatitis c virus replication
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
CR20210481A (es) Formulación sólida del modulador de ensamblaje de la cápside
AU2022401696A1 (en) Therapeutic compounds for hiv virus infection
MX2022007909A (es) Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
AU2022366587A1 (en) Novel capsid assembly inhibitors
MX2019009659A (es) Dosis mejorada de baloxavir marboxil para pacientes pediatricos.
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA202191109A1 (ru) Соединения 5-членного гетероарилкарбоксамида для лечения вируса гепатита в
MX2021016022A (es) Efecto sinergico de eyp001 e ifn para el tratamiento de la infeccion por hbv.
MX2019015236A (es) Uso de la rpobenecida y sus derivados como inhibidores de la neuraminidasa del virus de la influenza.
EA202192965A1 (ru) Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
PH12015502258A1 (en) Solid oral dosage formulation of hcv inhibitor in the amorphous state